GleamWall
中文EN

BIOE Bio Essence Corp

Pharmaceutical Preparations · OTC · SEC CIK 1723059 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY435.2%
TTM net income YoY943.9%
TTM EPS YoY—
Revenue 3-yr CAGR46.9%
Net income 3-yr CAGR—

Margins

Gross margin68.4%
Operating margin45.1%
Net margin44.7%
FCF margin—
EBITDA margin54.3%

Returns

ROE—
ROA64.7%
ROIC (approx.)—
Asset turnover1.45x

Leverage & solvency

Liabilities / assets42.7%
Debt / equity0.02x
Current ratio0.17x
Interest coverage-286.41x

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio39.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$253,020$794,711$500,537$1.48M$136,800$259,123$22,189$147,555
Cost of revenue$113,859$324,450$181,184$336,033$41,040$90,479$1,601$40,657
Gross profit$139,161$470,261$319,353$1.14M$95,760$168,644$20,588$106,898
SG&A expense$298,286$190,971$102,878$113,794$80,857$107,421$225,137$103,046
Operating income-$159,125$279,290$215,795$1.03M$14,253$61,223-$205,092$3,852
Interest expense-$3,508-$2,342$542$540$556$547$543$536
Pretax income-$155,625$280,488$215,212$1.03M$12,998$60,664-$205,752-$27,563
Income tax-$5,167$10,411$9,839$0$0$800—$0
Net income-$150,458$270,077$205,373$1.03M$12,998$59,864-$205,752-$27,563
EBITDA$15,875$382,890$215,854$1.03M$14,311$61,282-$205,033$3,910
EPS (basic)—————0.00-0.01—
EPS (diluted)—————0.00-0.01—
Balance sheet
Cash & equivalents$201,511$675$36,177—$28,741——$1,371
Receivables——$5,319$23,454$4,969$4,969$8,191$5,124
Current assets$278,919$606,507$788,994$422,377$184,378$112,477$365,444$280,692
Intangibles$3.22M$3.40M$38$97$3.22M$3.40M$274$332
Total assets$4.00M$4.00M$789,032$422,474$184,534$112,692$365,718$281,024
Current liabilities$1.65M$1.61M$2.16M$2.44M$3.23M$3.07M$3.24M$2.80M
Long-term debt$56,519$56,836$57,160$57,482$57,806$58,122$56,164$56,481
Total debt$56,519$56,836$57,160$57,482$57,806$58,122$56,164$56,481
Total liabilities$1.71M$1.66M$2.22M$2.50M$3.29M$3.23M$3.54M$3.25M
Shareholders' equity$2.29M$2.34M-$1.43M-$2.07M-$3.10M-$3.11M-$3.17M-$2.97M
Net debt-$144,992$56,161$20,983—$29,065——$55,110
Shares outstanding55.81M53.81M46.81M38.01M38.01M38.01M38.01M38.01M
Cash flow statement
Operating cash flow-$368,848$59,650-$411,970$1.24M$186,973$167,797-$26,069$423,066
Investing cash flow$470,000———————
Financing cash flow$99,684-$10,325$448,147-$1.27M-$158,232-$167,797$24,698-$451,513
Depreciation & amortization$175,000$103,600$59$59$58$59$59$58

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.